A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Capricor Therapeutics's Debt-to-EBITDA or its related term are showing as below:
CAPR'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.76 Med: -0.1 Max: -0.02
Current: -0.13
During the past 13 years, the highest Debt-to-EBITDA Ratio of Capricor Therapeutics was -0.02. The lowest was -0.76. And the median was -0.10.
CAPR's Debt-to-EBITDA is ranked worse than 100% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs CAPR: -0.13
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Capricor Therapeutics Debt-to-EBITDA Related Terms
Capricor Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Capricor Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAPR vs COAG, DMRA, MPLT: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Capricor Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Capricor Therapeutics (CAPR) has a Debt-to-EBITDA of -0.10 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Capricor Therapeutics. According to the industry distribution chart, Capricor Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry.
Is Capricor Therapeutics' Debt-to-EBITDA too high?
Capricor Therapeutics' current Debt-to-EBITDA is -0.10. Based on the distribution chart, Capricor Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Debt-to-EBITDA compare to COAG and DMRA?
According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Capricor Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Capricor Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Debt-to-EBITDA is -0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $21.50 — trading 341.5% above its estimated fair value. The current Debt-to-EBITDA is -0.10. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Debt-to-EBITDA is -0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $21.50 is trading 341.5% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Debt-to-EBITDA: -0.10
GF Value™: $4.87 vs. price of $21.50 (341.5% above fair value)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
